Skip to main content

Cancer

Watch: Cancer after Biologic Use in Patients with a History of Prior Malignancyhttps://t.co/46f4xsCj31 https://t.co/rr3EfgCSCF
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2022
Malignancy risk on b/tsDMARDs in patients with prior malignancy history For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz
Dr. John Cush @RheumNow( View Tweet )
Jun 06, 2022
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Jun 04, 2022

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded

Read Article
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
Meudec et al. Comparative effects of JAKi on NK cell function on cancer cells (lymphoma and lung cancer). Tofacitinib had most negative impact. Interesting given blanket black box based on tofa data! @RheumNow #EULAR2022 OP0265 https://t.co/XSE7hP60Ui https://t.co/MjtAJcvWAD
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 03, 2022
Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
acr_session2.jpeg

EULAR 2022 – Day 2 Report

Jun 02, 2022

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.

Read Article
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 02, 2022
Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
Spanish safety registry BIOBADASER 3.0: *9000+ pts with IMID treated w/ bio or tsDMARDS *352 pts w/ prior malignancy *32 incident malignancies -> 27 events/1000PY NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups @RheumNow #EULAR2022 OP0138 https://t.co/8IyC6NdGCF
Aurelie Najm @AurelieRheumo( View Tweet )
Jun 02, 2022
#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex @KDAO2011( View Tweet )
Jun 01, 2022
PSS.scleroderma.arthritis.contractures

Immune Checkpoint Inhibitor Associated Arthritis

May 30, 2022

Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

Read Article
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

May 20, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
Increased Cancer Risk with Autoimmune Disorders (AID) The incidence and mortality of cancer among AID was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.https://t.co/T2WkOWp0cA https://t.co/iNJioAvrIe
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Mar 31, 2022

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.



The cohort included 8,120 AID patients from a national tertiary referral

Read Article
IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
risk2h.jpg

Risk vs. Benefit Lessons from the ORAL Surveillance Study

Jan 27, 2022

In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Risk of Cancer w/ IgG4-related disease (IgG4-RD)? A meta-analysis of 10 studies shows compared to gen population, IgG4-RD has a higher risk of overall cancer(SIR 2.57), esp pancreatic (SIR 4.1) & lymphoma (SIR 69.2); but not lung or gastric cancer https://t.co/EzgMXIdFcL

Dr. John Cush @RheumNow( View Tweet )

Jan 06, 2022
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
×